Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Alliance Pharma PLC - Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines - Issues trading update for the six months to June 30. Expects revenue of £84.8 million, up 2.8% from £82.4 million a year prior. Consumer Healthcare revenues rise 5% to £61.4 million, prescription medicine revenues grows 3.4% to £23.3 million. Continues to expect group revenue to build throughout the second half, driving gross margin improvement which will be used to support further investment in marketing and innovation. Continues to anticipate that full-year profitability will be in line with financial 2023. Expects net debt and leverage to fall further in the second half, reflecting the group’s strong cash generation.
Current stock price: 38.05 pence
12-month change: down 25%
Copyright 2024 Alliance News Ltd. All Rights reserved.